Literature DB >> 28932533

A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay.

Lorenza Landi1, Federico Cappuzzo1.   

Abstract

Entities:  

Year:  2017        PMID： 28932533      PMCID： PMC5594179          DOI： 10.21037/jtd.2017.07.76

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Authors:  Justin F Gainor; Leila Dardaei; Satoshi Yoda; Luc Friboulet; Ignaty Leshchiner; Ryohei Katayama; Ibiayi Dagogo-Jack; Shirish Gadgeel; Katherine Schultz; Manrose Singh; Emily Chin; Melissa Parks; Dana Lee; Richard H DiCecca; Elizabeth Lockerman; Tiffany Huynh; Jennifer Logan; Lauren L Ritterhouse; Long P Le; Ashok Muniappan; Subba Digumarthy; Colleen Channick; Colleen Keyes; Gad Getz; Dora Dias-Santagata; Rebecca S Heist; Jochen Lennerz; Lecia V Sequist; Cyril H Benes; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman; Alice T Shaw
Journal:  Cancer Discov       Date:  2016-07-18       Impact factor: 39.397

2.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.

Authors:  Justin F Gainor; Daniel S W Tan; Tomasso De Pas; Benjamin J Solomon; Aziah Ahmad; Chiara Lazzari; Filippo de Marinis; Gianluca Spitaleri; Katherine Schultz; Luc Friboulet; Beow Y Yeap; Jeffrey A Engelman; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

3.  EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Authors:  Jussi P Koivunen; Craig Mermel; Kreshnik Zejnullahu; Carly Murphy; Eugene Lifshits; Alison J Holmes; Hwan Geun Choi; Jhingook Kim; Derek Chiang; Roman Thomas; Jinseon Lee; William G Richards; David J Sugarbaker; Christopher Ducko; Neal Lindeman; J Paul Marcoux; Jeffrey A Engelman; Nathanael S Gray; Charles Lee; Matthew Meyerson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

4.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

Authors:  Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Young Hak Kim; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Miyako Satouchi; Toshiyuki Kozuki; Takehito Shukuya; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Takashi Asakawa; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura
Journal:  Lancet       Date:  2017-05-10       Impact factor: 79.321

5.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

6.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Authors:  Alice T Shaw; Tae Min Kim; Lucio Crinò; Cesare Gridelli; Katsuyuki Kiura; Geoffrey Liu; Silvia Novello; Alessandra Bearz; Oliver Gautschi; Tony Mok; Makoto Nishio; Giorgio Scagliotti; David R Spigel; Stéphanie Deudon; Cheng Zheng; Serafino Pantano; Patrick Urban; Cristian Massacesi; Kalyanee Viraswami-Appanna; Enriqueta Felip
Journal:  Lancet Oncol       Date:  2017-06-09       Impact factor: 41.316

7.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

Authors:  Jean-Charles Soria; Daniel S W Tan; Rita Chiari; Yi-Long Wu; Luis Paz-Ares; Juergen Wolf; Sarayut L Geater; Sergey Orlov; Diego Cortinovis; Chong-Jen Yu; Maximillian Hochmair; Alexis B Cortot; Chun-Ming Tsai; Denis Moro-Sibilot; Rosario G Campelo; Tracey McCulloch; Paramita Sen; Margaret Dugan; Serafino Pantano; Fabrice Branle; Cristian Massacesi; Gilberto de Castro
Journal:  Lancet       Date:  2017-01-24       Impact factor: 79.321

8.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

9.  Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Authors:  Sai-Hong Ignatius Ou; Jin Seok Ahn; Luigi De Petris; Ramaswamy Govindan; James Chih-Hsin Yang; Brett Hughes; Hervé Lena; Denis Moro-Sibilot; Alessandra Bearz; Santiago Viteri Ramirez; Tarek Mekhail; Alexander Spira; Walter Bordogna; Bogdana Balas; Peter N Morcos; Annabelle Monnet; Ali Zeaiter; Dong-Wan Kim
Journal:  J Clin Oncol       Date:  2015-11-23       Impact factor: 44.544

10.  Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Chad G Rusthoven; Robert C Doebele
Journal:  J Clin Oncol       Date:  2016-06-13       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.